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The LIN28/let-7 Pathway in Cancer
Julien Balzeau †, Miriam R. Menezes †, Siyu Cao † and John P. Hagan*
Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA
Among all tumor suppressor microRNAs, reduced let-7 expression occurs most
frequently in cancer and typically correlates with poor prognosis. Activation of
either LIN28A or LIN28B, two highly related RNA binding proteins (RBPs) and
proto-oncogenes, is responsible for the global post-transcriptional downregulation of
the let-7 microRNA family observed in many cancers. Specifically, LIN28A binds the
terminal loop of precursor let-7 and recruits the Terminal Uridylyl Transferase (TUTase)
ZCCHC11 that polyuridylates pre-let-7, thereby blocking microRNA biogenesis and
tumor suppressor function. For LIN28B, the precise mechanism responsible for let-7
inhibition remains controversial. Functionally, the decrease in let-7 microRNAs leads
to overexpression of their oncogenic targets such as MYC, RAS, HMGA2, BLIMP1,
among others. Furthermore, mouse models demonstrate that ectopic LIN28 expression
is sufficient to drive and/or accelerate tumorigenesis via a let-7 dependent mechanism. In
this review, the LIN28/let-7 pathway is discussed, emphasizing its role in tumorigenesis,
cancer stem cell biology, metabolomics, metastasis, and resistance to ionizing radiation
and several chemotherapies. Also, emerging evidence will be presented suggesting that
molecular targeting of this pathway may provide therapeutic benefit in cancer.
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INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs (∼19–22 nucleotides in length) that play critical
roles in post-transcriptional gene regulation (reviewed in Hagan and Croce, 2007; Lin and Gregory,
2015b; Connerty et al., 2016). In general, microRNAs are generated by a two-step process where the
primary microRNA (pri-miR) transcript is cleaved in the nucleus by the Microprocessor complex
to generate precursor microRNA (pre-miR) with a characteristic stem-loop structure. The pre-miR
is exported to the cytoplasm where Dicer is responsible for generating the mature miRNA that is
incorporated into the microRNA-induced silencing complex (miRISC). To exert their biological
effect, microRNAs most frequently bind with imperfect complementarity to the 3′ UTR of their
targets mRNAs leading to mRNA decay and/or translational inhibition. Studies using genetically
engineered mouse models have revealed that miRNAs serve diverse functions in developmental
and physiological processes.
Dysregulated microRNA expression is associated with and functionally significant for many
diseases including cancer. Of note, a recent study systemically evaluated the prognostic value
of miRNA expression in human cancers (Nair et al., 2012). Specifically, decreased expression of
the tumor suppressor let-7 microRNAs and increased expression of oncogenic miR-21 are most
frequently associated with poor prognosis as determined by analysis of 46 studies on 20 different
types of human cancers. The coordinate repression of the let-7 microRNA family is striking for two
reasons. First, there are 12 members of the let-7 microRNA family located on eight chromosomes,
where most cells express a handful of let-7 family members. Secondly, primary let-7 transcripts are
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still being actively transcribed in many cancers as well as
in embryonic stem cells; however, mature let-7 is not being
produced as expected. Ultimately, two highly conserved RNA-
binding proteins, LIN28A and LIN28B, were shown to inhibit
biogenesis of mammalian let-7 miRNAs through direct binding
to either pre-let-7 and/or pri-let-7 (Heo et al., 2008, 2009;
Newman et al., 2008; Rybak et al., 2008; Viswanathan et al., 2008;
Hagan et al., 2009; Piskounova et al., 2011). Strikingly, we showed
that inhibition of either LIN28A or LIN28B via siRNA led to
regression of established human xenograft tumors in mice that
expressed the targeted gene (Piskounova et al., 2011). This result
was recapitulated by restoring let-7 expression using amicroRNA
mimic, implicating let-7 dependent functions of LIN28AB in
tumor regression. For clarity throughout this review, LIN28AB
will be used to refer collectively to both LIN28A and LIN28B.
Also, it is worth noting thatmany publications refer to LIN28 (the
official gene name for LIN28A) when in reality the study involved
LIN28B.
In addition to miRNAs, cancer stem cells (CSCs) represent
another important target for the design of novel anticancer
treatments. Unlike differentiated cancer cells present in many
tumors, CSCs are a rare tumor cell population that has stem
cell-like properties and are sufficient in small numbers to
regrow tumors. They have the ability of self-renewal and can
differentiate into heterogeneous types of tumor cells (O’Connor
et al., 2014). While frontline cancer treatments are often effective
against the bulk of the tumor, most chemotherapeutic drugs
show poor efficacy against CSCs. Considerable evidence has
shown that CSCs is one of the underlying mechanisms of
tumor resistance to chemotherapy and radiation therapy and
are often responsible for recurrence of more deadly disease.
Not surprisingly, expression of LIN28A or LIN28B serves
as CSC biomarkers in multiple cancers (Zhou et al., 2013).
FIGURE 1 | Schematic of human LIN28A and LIN28B proteins. These highly related proto-oncogenes have two distinct RNA binding regions. The first is a
cold-shock domain (highlighted in blue) with preference for GNGAY RNA sequences while the CCHC Zn fingers (highlighted in green) bind preferentially to a GRAG
motif (R = G or A). Binding to both RNA sites is required for high affinity pre-let-7 binding. Putative nucleolar localization signal (NoLS) and nuclear localization signal
(NLS) are reported for LIN28B.
LIN28AB directly contributes to the regulation and maintenance
of stemness of CSCs. Moreover, LIN28AB via a let-7 dependent
mechanism confers resistance to ionizing radiation and several
chemotherapies.
STRUCTURE AND KEY BIOLOGICAL
FUNCTIONS OF LIN28A AND LIN28B
Lin-28 and let-7 were first discovered and studied in the
nematode Caenorhabditis elegans as heterochronic genes that
regulate developmental timing (Moss et al., 1997; Reinhart et al.,
2000; Slack et al., 2000). In worms tomammals, Lin28 blocks let-7
expression, while let-7 itself binds to the 3′ UTR of Lin28 mRNA
to regulate negatively Lin28 expression, thereby establishing a
double negative feedback loop. In mammals, there are two LIN28
family members. The human LIN28A and LIN28B genes encode
209- and 250-amino acid proteins, respectively (Figure 1). Both
RNA binding proteins (RBPs) share a high degree of homology
in structural domains with an N-terminal cold-shock domain
(CSD) and two C-terminal CysCysHisCys (CCHC) zinc finger
domains (Guo et al., 2006). Crystallography and biochemical
studies demonstrate that the CSD and Zinc finger domains
bind GNGAY and GGAG motifs in the pre-let-7 terminal loop,
respectively (Nam et al., 2011; Figure 2). The CSD and Zinc
finger domains are separated by a flexible region that permits
binding to distinct pre-let-7 loops where the GNGAY and GGAG
motifs vary in their spacing. Protein interactions with both RNA
sequence motifs are required for high affinity binding.
To unravel the in vivo function of Lin28ab in mammals, we
in collaboration with the Daley lab generated and characterized
conditional mouse knockouts of both genes (Shinoda et al.,
2013). Lin28a null mice experience early perinatal lethality,
while Lin28b knockout leads to postnatal growth defects solely
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in males. Double knockout causes embryonic lethality by E13
suggesting that these proteins have functional redundancy during
development. Overall, Lin28a and Lin28b expression is largely
restricted to embryonic development in mammals. Consistent
with this observation, conditional mouse knockout of either gene
at 6 weeks of age in mice yields no overt phenotypes. During
differentiation, the levels of Lin28AB are markedly reduced
with a concomitant increase in let-7 microRNAs (Mayr and
Heinemann, 2013; Figure 3). LIN28A is predominantly/almost
exclusively cytoplasmic and has been detected in association with
ribosomes, P-bodies, and stress granules (Balzer andMoss, 2007).
For LIN28B, there are divergent opinions with regards to its
subcellular localization. A report found that LIN28B has distinct
nucleolar and nuclear localization signals (Piskounova et al.,
2011), while other research found that LIN28B is predominantly
cytoplasmic and suggest that it may shuttle into the nucleus
in a cell-cycle dependent manner (Guo et al., 2006; Molenaar
et al., 2012; Hafner et al., 2013). Further studies are required to
elucidate fully the exact subcellular location of human LIN28B
that may vary dependent on cell type. This knowledge will
inform the precise mechanism(s) by which LIN28B blocks let-7
biogenesis.
LIN28A and/or LIN28B are implicated in key biological
functions such as development, glucose metabolism, and
pluripotency via let-7 dependent and independent mechanisms
(Zhu et al., 2011; Mayr and Heinemann, 2013; Zhang et al., 2016).
Studies have shown that LIN28A is a stem cell pluripotency
factor. Using OCT4, SOX2, NANOG, and LIN28A, adult
human fibroblasts were successfully reprogrammed into induced
pluripotent stem cells (Yu J. et al., 2007). Of note, three of the four
FIGURE 2 | Alignment of human pre-let-7 sequences (partial) with a focus on the terminal loop. The bases shown in red font are part of the let-7-5p/let-7-3p
microRNA duplex following cytoplasmic Dicer cleavage. Black boxes and asterisks denote perfectly conserved bases while blue boxes represent bases where 10/12
are identical across all let-7 family members. Note that the GRAG (9 GGAG > 2 GAAG) motif is conserved across all family members except human let-7a-3 that is
reported to escape LIN28AB-mediated repression. This RNA sequence motif is bound by the CCHC zinc fingers while the cold shock domain binds the GNGAY motif
(and close variants) that lies at varying distances 5′ of the GGAG motif.
FIGURE 3 | The LIN28AB/let-7 axis has significant biological functions. LIN28AB expression is high in undifferentiated cells where these proteins block
biogenesis of the let-7 microRNA family. As differentiation progresses, LIN28AB expression is lost, resulting in production of mature let-7 microRNAs that themselves
negatively regulate LIN28AB. During cellular transformation, wound healing (in particular in young mammals), and in the generation of iPSCs, LIN28AB helps drive
pluripotency, self-renewal, de-differentiation, and/or cellular transformation.
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Yamanaka factors transactivate LIN28A expression and LIN28A
on its own is sufficient for reprogramming (Hanna et al., 2009).
Repression of let-7 miRNAs is important in establishing the
pluripotent state. Let-7 miRNAs directly repress a pantheon of
well-known oncogenes such as RAS, MYC, HMGA2, BLIMP1,
among others (Figures 4, 5; Zhou et al., 2013). In addition,
LIN28AB is thought to alter cellular bioenergetics and glucose
metabolism that has direct cancer implications. The role of
LIN28AB in metabolism will be discussed in greater detail later
in this review.
LIN28A AND LIN28B BLOCK BIOGENESIS
OF THE TUMOR SUPPRESSOR LET-7
MICRORNA FAMILY
Given the observation that global let-7 microRNA biogenesis
was blocked in multiple cellular contexts, several research teams
interrogated the responsible mechanism (Heo et al., 2008, 2009;
Newman et al., 2008; Rybak et al., 2008; Viswanathan et al.,
2008; Hagan et al., 2009; Piskounova et al., 2011). When taken
together, the consensus is that cytoplasmic Lin28A first binds
FIGURE 4 | The LIN28AB/let-7 axis has significant impact on cancer hallmarks. LIN28AB through let-7 dependent and independent mechanisms promote
multiple processes that promote cancer development and progression.
FIGURE 5 | Model for LIN28A/ZCCHC11 regulation of let-7 microRNA biogenesis, promoting cellular proliferation and modifying bioenergetics. LIN28A
recruits the TUTase ZCCHC11 to pre-let-7 where ZCCHC11 adds a short polyU tail to pre-let-7. Pre-let-7 is no longer a DICER substrate and is targeted for
degradation by DIS3L2, thereby blocking let-7 maturation into its functional tumor suppressor form. Loss of mature let-7 microRNAs causes overexpression of
numerous oncogenes and bioenergetic genes.
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to the conserved terminal loop of pre-let-7 and recruits the
TUTase Zcchc11 (also known as TUT4) to polyuridylate pre-let-
7, thereby blocking Dicer cleavage (Figure 5; Hagan et al., 2009;
Heo et al., 2009; Thornton et al., 2012). Polyuridylated pre-let-
7 is degraded by the exonuclease Dis3L2, a gene implicated in
Perlman Syndrome gene (Chang et al., 2013; Ustianenko et al.,
2013; Faehnle et al., 2014). Of note, loss of Dis3L2 does not
elevate mature let-7 levels, since polyuridylated pre-let-7 is a very
poor Dicer substrate. A recent study suggested that the TUTase
Zcchc6 (also known as TUT7) may be partially redundant with
Zcchc11 in Lin28A-mediated let-7 repression (Thornton et al.,
2012). Specifically, knockdown of Zcchc6 did not change mature
let-7 levels on its own; however, knockdown of both Zcchc11
and Zcchc6 led to an increase in let-7 levels in comparison
to single Zcchc11 knockdown. In contrast to this result, loss
of ZCCHC11 via siRNA on its own was sufficient to cause
regression of established LIN28A-positive tumor xenografts to a
similar level as LIN28A knockdown, raising doubts on TUTase
redundancy in let-7 repression in LIN28A-positive human cancer
cells (Piskounova et al., 2011). To date, no other reports have been
published that have independently tested TUTase redundancy in
LIN28A-mediated let-7 repression.
With regards to suppression of let-7, there are four distinct
modes of action that have been hypothesized where multiple
mechanisms may be responsible or have differential significance
based on cell type. The first model suggested that LIN28B
binds pri-let-7 in the nucleus, blocking Microprocessor cleavage
(Newman et al., 2008; Viswanathan et al., 2008). A second model
is that LIN28B likely binds pre-let-7 in the cytoplasm, blocking
Dicer cleavage (Rybak et al., 2008). The third model is that
LIN28B directs polyuridylation of pre-let-7 via an unidentified
TUTase, blocking Dicer cleavage and leading to degradation
of polyuridylated pre-let-7 (Heo et al., 2008). Of note, CLiP-
Seq of DIS3L2-associated RNAs identified polyuridylated pre-
let-7 in the LIN28B-positive HEK-293T cell line (Ustianenko
et al., 2016). The final model demonstrated that LIN28B does
not require the TUTase ZCCHC11 to block let-7 biogenesis and
proposed that LIN28B blocks let-7 biogenesis by sequestering
pri-let-7 in the nucleolus (Piskounova et al., 2011); however, the
functional consequence of another TUTase ZCCHC6 was not
investigated in this study. This omission is notable as subsequent
work from the Gregory lab showed that LIN28B promotes pre-
let-7 in vitro uridylation by ZCCHC6 (Thornton et al., 2012).
Since the subcellular localization of LIN28B is controversial, the
precise mechanisms of LIN28B-mediated let-7 repression and
whether or not LIN28B utilizes a TUTase for let-7 repression
remains unclear.
LET-7 INDEPENDENT FUNCTIONS OF
LIN28AB IN POST-TRANSCRIPTIONAL
GENE REGULATION
Besides let-7 miRNAs, LIN28AB also functions in post-
transcriptional gene regulation by directly binding to specific
mRNAs leading to altered translational efficiency. For example,
Insulin-like growth factor 2 (Igf2) was one of the first mRNAs
discovered to be bound by Lin28A (Polesskaya et al., 2007).
In skeletal myoblasts, Lin28A enhances Igf2 expression by
recruiting Igf2 mRNA to polysomes through interactions with
translation initiation complexes. In human embryonic stem cells,
LIN28A acts as a post-transcriptional regulator for OCT4, a
reprogramming factor. This study demonstrated that LIN28A
promoted translation of OCT4 by directly binding within coding
region of its mRNA via interaction with RNA helicase A (RHA;
Qiu et al., 2010). Other studies using mouse ESCs uncovered
the association of Lin28A with more mRNA targets including
histone H2a, Cyclin A, Cyclin B and CDK4. Lin28A facilitates
the expression of these mRNAs by directly binding to either their
coding region (Xu and Huang, 2009) or 3′ untranslated region
(3′-UTR; Xu et al., 2009). Interestingly, a recent study conducted
by Daley’s group found that Lin28A expression enhanced adult
tissue repair in a mouse model by reprogramming cellular
bioenergetics (Shyh-Chang et al., 2013b). This study showed that
let-7 suppression was necessary but not sufficient to improve
tissue repair. Enhanced translation of a several metabolic
enzymes due to Lin28a was also required. To investigate if
there is a consensus LIN28A binding motif in mRNAs and
the global impact of LIN28A on mRNA expression, Wilbert
and colleagues conducted a study employing crosslinking and
immunoprecipitation coupled with high-throughput sequencing
(CLiP-Seq) in human ES and somatic cells (Wilbert et al.,
2012). It was found that, similar to its interaction with
precursor let-7 miRNA transcripts, LIN28A binds to a consensus
GGAGA motif enriched within coding exons and 3′-UTR of
mRNAs. In the study, a positive feed-forward autoregulation
of LIN28A was revealed where LIN28A directly amplifies
its own translation by binding to sites within 3′-UTR of
its mRNA. Furthermore, LIN28A-mediated post-transcriptional
regulation was also responsible for the expression of several
RBPs. Increased levels of LIN28A induced widespread changes
in alternative splicing indicating LIN28A-mediated regulation
of splicing factors. In a recent study, similar results were
obtained for LIN28B using photoactivatable-ribonucleoside-
enhanced crosslinking and immunoprecipitation (PAR-CLIP) on
HEK293 cells (Hafner et al., 2013).
CLINICAL RELEVANCE AND ROLE OF
LIN28A/LIN28B IN CANCER
Reactivation of either LIN28A or LIN28B is a hallmark of
many human cancers where the expression of these proto-
oncogenes is typically mutually exclusive. Table 1 lists multiple
studies that have evaluated the diagnostic and prognostic value of
LIN28A, LIN28B, and/or let-7 expression in cancer. Altogether,
these studies demonstrate the LIN28AB expression and let-7
loss almost invariably correlates with poor prognosis. As tumor
suppressors, let-7 miRNAs repress several oncogenes including
K-RAS, C-MYC, HMGA2 and cell cycle factors (Cyclin D1,
D2; Roush and Slack, 2008). Under pathological conditions,
loss of let-7 expression triggers derepression of these oncogenes
leading to tumorigenesis or facilitating tumor growth and/or
metastasis. LIN28A and LIN28B inhibit biogenesis of all let-7
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TABLE 1 | Clinical relevance of LIN28A/LIN28B expression in human cancers.
Cancer type Sample size Detection method Clinical relevance References
20 cancer types Meta-analysis of
46 studies
Of all tumor suppressor microRNAs, let-7 loss most
frequently correlated with poor prognosis across cancers
Nair et al., 2012
Acute myeloid leukemia (AML) 108 IHC LIN28B↑ poorer prognosis Zhou et al., 2016
Atypical teratoid/rhabdoid tumor 24 IHC, RT-qPCR 19/24 tumors express LIN28A, many tumors also
express LIN28B by RT-qPCR
Weingart et al., 2015
Brain cancers (Pediatric) 450 FISH, IHC LIN28A/B serves as a diagnostic marker for pediatric
brain tumors
Spence et al., 2014
Breast cancer 15 IHC LIN28A↑ higher grade Viswanathan et al., 2009
Breast cancer 33 IHC, RT-qPCR 9/33 LIN28A-positive (correlates with HER2+), 10/33
LIN28B-positive (correlates with triple negative)
Piskounova et al., 2011
Breast cancer 569 IHC 174/569 had high LIN28A and were characterized by
worse prognosis, LIN28A expression associated with
HER2+ tumors
Feng et al., 2012
Cervical cancer 11 IHC LIN28A↑ higher grade Viswanathan et al., 2009
Chronic myeloid leukemia (CML) 35 RT-qPCR LIN28A↑ in accelerated phase & blast crisis CML in
comparison to chronic phase
Viswanathan et al., 2009
Colon cancer 45 IHC 19/45 LIN28A-positive, 14/45 LIN28B-positive Piskounova et al., 2011
Colon cancer 228 Tissue microarray, IHC LIN28B↑ reduced patient survival and higher probability
of tumor recurrence
King et al., 2011
Colon cancer 357 IHC LIN28B↑ reduced survival and higher disease recurrence Pang et al., 2014
Colorectal cancers 595 IHC 10% LIN28A+, 8% LIN28B, 20% LIN28A+/LIN28B+,
LIN28A↑ reduced survival
Tu et al., 2015
Esophageal cancer 161 IHC Either LIN28A or LIN28B↑ more aggressive tumors and
poor prognosis
Hamano et al., 2012
Gastric cancer 239 RT-PCR, IHC LIN28A↑ poor prognosis Xu et al., 2013
Gastric cancer 47 IHC LIN28A as a predictive biomarker for neoadjuvant
chemotherapy
Teng et al., 2013
Gastric cancer 298 IHC, RT-qPCR LIN28A↑ poor prognosis. It can be used as a prognostic
factor in chemotherapy
Wang et al., 2014
Gastric cancer 97 IHC LIN28A↑ poor prognosis Hu et al., 2014
Germ cell tumors (Extragonadal) 131 IHC LIN28A as a sensitive marker for primary extragonadal
seminoma/germinomas, embryonal carcinoma, and yolk
sac tumors with high specificity
Cao et al., 2011b
Glioblastoma multiforme (GBM) 107 Gene microarray, Tissue
microarray
LIN28A↑ shortened overall and progression-free survival Qin et al., 2014
Glioma (pediatric and *adult) 139+ TCGA IHC, RT-qPCR LIN28A↑ more common in high grade/GBM, 42% of
GBM express either LIN28A or LIN28B
Mao et al., 2013
Liver cancer 89 Microarray LIN28B↑ higher disease recurrence and associated with
advanced stage
Viswanathan et al., 2009
Liver cancer 129 RT-qPCR LIN28A↑ prognostic factor for poor overall survival Qiu et al., 2012
Medulloblastoma 90 Microarray LIN28B↑ and let-7↓ correlated with poor prognosis in
Group 3 and Group 4 subtypes
Northcott et al., 2009
Medulloblastoma 238 RNA-Seq LIN28B↑ and let-7↓ correlated with poor prognosis in
Group 3 and Group 4 subtypes
Hovestadt et al., 2014
Multiple Myeloma 542 Microarray LIN28B↑ poor prognosis Manier et al., 2016
Neuroblastoma 2817 SNP array, RT-qPCR,
microarray
LIN28B↑ poor prognosis Diskin et al., 2012
Oral squamous cell carcinoma 12 RT-qPCR Higher expression of LIN28A in the neoplastic samples Sterenczak et al., 2014
Increased levels of LIN28B could be associated with
poor prognosis OSCCs
Ovarian primitive germ cell tumors 121 IHC LIN28A is sensitive diagnostic marker for ovarian germ
cell tumors
Xue et al., 2011
Ovarian cancer (Epithelial) 140 RT-qPCR, IHC High LIN28B and IMP3 is associated with poorer
prognosis
Hsu et al., 2015
(Continued)
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TABLE 1 | Continued
Cancer type Sample size Detection method Clinical relevance References
Ovarian cancer (Epithelial) 211 SNP assay, RT-qPCR LIN28B↑ higher mortality rate and increased relapse risk Lu et al., 2012
Ovarian cancer Multiple datasets Microarray, RT-qPCR LIN28B↑ in C5 Ovarian Cancer Helland et al., 2011
Pheochromo-cytomas and
Paragangliomas
208 Tissue microarray LIN28A expression is associated with mutations in one
of the succinate dehydrogenase genes
Oudijk et al., 2015
Primitive neuroectodermal tumor 51 Microarray, IHC, RT-qPCR LIN28A is a promising prognostic marker Picard et al., 2012
Primitive neuroectodermal tumors
(Supratentorial)
47 IHC High LIN28A and OLIG2 is associated with poorer
prognosis
Choi et al., 2016
Prostate cancer 42 IHC LIN28B promotes growth and activates androgen
receptor
Tummala et al., 2013
Prostate cancer 41 IHC LIN28AB higher in metastatic tumor than primary,
expression inversely correlated with ESE3/EHF
Albino et al., 2016
Testicular germ cell tumor 184 IHC LIN28A was a highly sensitive diagnostic marker for
testicular germ cell tumors
Cao et al., 2011a
Wilms tumor 105 IHC LIN28B overexpression is related to higher risks of
relapse and poor survival
Urbach et al., 2014
miRNAs with the possible exception of let-7a-3 (Triboulet et al.,
2015), implicating the coordinate downregulation of this tumor
suppressor microRNA family in disease. In fact, high levels
of LIN28A or 28B are found in many human cancers such
as glioblastoma, ovarian, gastric, prostate, and breast cancer
(Dahiya and Morin, 2010; Cai et al., 2013; Qin et al., 2014). In
cases where a specific cancer type expresses both LIN28A and
LIN28B, these tend to occur in distinct tumor subtypes. As an
example, HER2+ breast cancer typically expresses LIN28A, while
triple negative breast cancer is LIN28B (Piskounova et al., 2011;
Yang J. et al., 2015; Shen et al., 2016). A study conducted by
Viswanathan and colleagues using primary human tumors and
human cancer cell lines showed that about 15% of human cancers
displayed high LIN28A/LIN28B and low let-7 expression pattern.
Overexpression of LIN28A/LIN28B is related with advanced
disease stage amongmultiple tumor types and typically associates
with poor prognosis (Viswanathan et al., 2009). Results from
another study showed that LIN28B promotes oncogenesis and
tumor progression in head and neck cancer cells by repressing
let-7 miRNAs (Alajez et al., 2012). Subsequent activation of let-7
targets such as HMGA2, CCND2, IGF1R, and IGF2BP2 was also
validated.
Activation of LIN28AB expression in cancer cells can be
triggered by upstream transcriptional factors and/or loss of
transcriptional repressors (Figure 6); however, much remains
to be discovered about how transcription of these two
genes is regulated. In breast cancer cells, depletion of C-
MYC by siRNA decreased LIN28A transcript and protein
level, whereas overexpression of C-MYC restored LIN28A
expression (Dangi-Garimella et al., 2009). Activation of LIN28B
by C-MYC has also been confirmed in multiple human
and mouse tumor models (Chang et al., 2009; Jiang et al.,
2012). Direct association of c-MYC with LIN28B promoter
led to transcriptional transactivation of the protein and
LIN28B expression was necessary and sufficient for MYC-
mediated Let-7 suppression. These results establish a positive
feedback loop between LIN28A/LIN28B and C-MYC. Whereas,
FIGURE 6 | Transcriptional networks that regulate LIN28B expression.
LIN28B is highly expressed during embryogenesis and as differentiation
progresses, LIN28B expression is lost. In adult mammals, only a small subset
of somatic cells exist where LIN28B expression occurs. Several transcription
factors such as MYC and NF-κB promote LIN28B transcription, while REST
and ESE3/EHF are transcriptional repressors.
LIN28A/LIN28B depresses C-MYC by repressing let-7 miRNAs,
C-MYC post-transcriptionally activates expression of LIN28A
and LIN28B. In another study, LIN28B was found to link
molecularly inflammation and cancer via a positive feedback
loop involving NF-κB activation and derepression of the let-
7 regulated gene IL-6 (Iliopoulos et al., 2009). In addition,
both genetic and epigenetic events contribute to LIN28B
expression in a subset of cancers (Viswanathan et al., 2009).
In rare cases, LIN28B expression may be activated in part
through genomic amplification or in Wilms tumor by a
chromosomal translocation. Epigenetic regulation via LIN28B
promoter hypomethylation may poise the LIN28B locus for
transcriptional activation. In contrast to LIN28AB reactivation
in adult cancer, some childhood cancers may be derived from
cells that failed to silence LIN28AB expression that acquired
additional genetic mutations. These childhood cancers include
atypical teratoid/rhabdoid tumors (AT/RT), pediatric CNS-
PNET, Wilms tumor, medulloblastoma, and neuroblastoma.
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TABLE 2 | LIN28 in cancer stem cells.
Cancer type CSC population LIN28A or LIN28B References
Breast cancer ALDH1+, high Vimentin, low E-cadherin LIN28A Cai et al., 2013
Breast cancer SOX2+, Nestin+, GFAP+, Synaptophysin LIN28A Mao et al., 2013
Breast cancer ALDH1+ LIN28A Yang et al., 2010
Breast cancer IMP2 LIN28A/B Degrauwe et al., 2016
Breast cancer High CD24, Low CD44 LIN28B Iliopoulos et al., 2009
Breast cancer CD44 +, CD24- LIN28A Cai et al., 2013
Colon cancer LGR5+, PROM1+ LIN28B King et al., 2011
Lung cancer (Non-small cell) CD166+ LIN28B Zhang et al., 2012
Oral carcinoma IGFBP5+. POSTN+ LIN28A Hayashi et al., 2013
Ovarian cancer Oct4+ LIN28A Peng et al., 2010
Ovarian cancer ALDH1+ LIN28A Yang et al., 2010
Ovarian cancer CD44+, CD24+, Epcam+, Ecadherin- LIN28A Meirelles et al., 2012
Pancreatic cancer ABCG2+, Nestin+ LIN28A Hamada et al., 2012
Prostate cancer Sox2+, Nanog+, Oct4+ LIN28B Kong et al., 2010
Prostate cancer ESE3/EHF LIN28A/B Albino et al., 2016
TABLE 3 | LIN28 and let-7 in resistance to anticancer therapies.
Cancer type LIN28 or let-7 Treatments References
Breast cancer LIN28A Paclitaxel Lv et al., 2012
Breast cancer LIN28A Radiation Wang et al., 2013
Breast cancer let-7a, b, c, d, e, f, g, i Tamoxifen Zhao et al., 2011
Breast cancer let-7b 5-Fluorouracil, Doxorubicin Wang et al., 2015
Breast cancer let-7e Doxorubicin Lv et al., 2014
Gastric cancer LIN28A Oxaliplatin, Paclitaxel, Doxorubicin, Fluorouracil Teng et al., 2015
Gastric cancer let-7b Cisplatin, Vincristine Yang X. et al., 2015
Glioblastoma multiforme let-7a, b, c, d, e, f, g, i Radiation Chaudhry et al., 2010
Hepatocellular Cancer LIN28A Paclitaxel Tian et al., 2014
Hepatocellular Cancer let-7g 5-Fluorouracil Tang et al., 2014
Lung cancer LIN28A Radiation Oh et al., 2010
Lung cancer LIN28B Radiation Jeong et al., 2009
Oral cancer let-7d Cisplatin/paclitaxel Chang et al., 2011
Ovarian cancer LIN28A Doxorubicin/Cisplatin Meirelles et al., 2012
Ovarian cancer LIN28B Paclitaxel Yan et al., 2014
Ovarian cancer let-7g Doxorubicin Boyerinas et al., 2012
Pancreatic cancer LIN28A Radiation Oh et al., 2010
Pancreatic cancer let-7b, c, d, e Gemcitabine Li et al., 2009
Pancreatic cancer let-7a Gemcitabine Bhutia et al., 2013
Prostate cancer LIN28A Enzalutamide, Abiraterone, Bicalutamide Tummala et al., 2016
Renal cell carcinoma let-7b, c 5-Fluorouracil Peng et al., 2015
In addition to the LIN28AB/let-7 axis, LIN28AB might
also induce oncogenesis through other signaling pathways.
For example, a MLL-fusion/MYC/LIN28A–|miR-150–|
FLT3/MYB/HOXA9/MEISI signaling pathway was recently
identified where LIN28A-mediated inhibition of miR-150
maturation is the pivotal step of leukemogenesis (Jiang et al.,
2012). A recent study showed that LIN28A binds to bone
morphogenetic proteins 4 (BMP4) mRNA promoting its
expression at a post-transcriptional level in ovarian cancer cells
(Ma et al., 2013). Overexpression of BMPs increases ovarian CSCs
proliferation and promotes tumor growth (McLean et al., 2011).
When combined with tumor cells in vivo, ovarian carcinoma-
associated mesenchymal stem cells enhanced proliferation of
ovarian CSCs and tumorigenesis through increased BMPs
expression. Furthermore, in vitro treatment with exogeneous
BMP2 increased growth of ovarian CSCs, whereas in vitro and in
vivo inhibition of BMP signaling partly abrogated mesenchymal
stem cell-induced tumor growth (McLean et al., 2011). Thus, the
finding provides a new regulation mechanism of ovarian tumor
growth by LIN28A and the potential for the development of
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novel treatment strategies against ovarian cancer. LIN28A was
also found to activate the translation of human epidermal growth
factor receptor 2 (HER2) and HMGA1 by directly interacting
with their mRNA in breast cancer cells (Feng et al., 2012).
LIN28A/LIN28B IN CSCs, METASTASIS,
AND RESISTANCE TO CHEMOTHERAPY
AND RADIOTHERAPY
Cancer stem cells (CSCs) play a pivotal function in numerous
pathological events during tumorigenesis and tumor progression
(O’Connor et al., 2014; Takahashi et al., 2014). Many frontline
therapies fail to eradicate cancer fully due to their failure to
kill CSC and the ability of CSCs to initiate tumor relapse, to
promote metastasis, and to confer resistance to chemotherapy
and radiation therapy. Therefore, the development of novel
therapeutics requires the elucidation of the contributing genetic
factors that lead to CSC-dependent aggressive pathology. There
is accumulating evidence showing that LIN28A/LIN28B is
important in the formation of CSCs in certain cancer types
and many consider them as biomarkers for CSCs (Table 2;
Viswanathan and Daley, 2010). In addition, LIN28AB expression
and let-7 loss has been associated with resistance to numerous
cancer therapies (Table 3).
Aldehyde dehydrogenase 1 (ALDH1) is a widely accepted
biomarker for CSCs in multiple cancers. A recent study showed
that LIN28A expression was positively correlated with a higher
percentage of ALDH1 positive cancer cells and is important
in maintaining these cells (Yang et al., 2010). In the study,
a double-negative feedback loop between LIN28A and let-7
mechanism. Another study provided some intriguing results on
the role of LIN28A in the epithelial-to-mesenchymal transition
(EMT), an important characteristic of CSCs, and stemness in
breast cancer cells (Liu et al., 2013). It was reported that
LIN28A significantly induced EMT via down-regulation of let-
7 microRNAs including let-7a. Furthermore, LIN28A expression
was shown to promote adherence and migration in cancer cells
and is correlated with tumor invasiveness. Expression of stem cell
factors such as NANOG, SOX2, OCT4, and LIN28B was found to
be upregulated in prostate cancer cells with an EMT phenotype
(Kong et al., 2010). Down-regulation of LIN28B reduced self-
renewal ability and increased let-7 level in these prostate cancer
cells. In non-small cell lung cancer, overexpression of LIN28B
and glycine decarboxylase, a metabolic enzyme, was required for
tumorigenesis and growth of CSCs (Zhang et al., 2012).
NIH-3T3 cells overexpressing either murine Lin28a or
human LIN28B generated tumors capable of local invasion
in nude mice (Viswanathan and Daley, 2010). There is a
growing body of evidence demonstrating that overexpression of
LIN28 and/or down-regulation of let-7 contributes to metastasis
and tumor resistance to chemotherapy and radiation therapy
(Table 3). For example, Raf kinase inhibitory protein (RKIP)
negatively regulates the MAP kinase, G protein-coupled receptor
kinase-2 and NF-κB signaling cascades. Overexpression of
RKIP enhances chemotherapeutic drug-induced apoptosis in
cancer cells (Odabaei et al., 2004). In an orthotopic murine
breast cancer model, RKIP effectively suppresses invasion by
metastatic breast cancer cells in vitro and inhibits tumor cell
intravasation and bone metastasis in vivo (Dangi-Garimella
et al., 2009). The underlying mechanism of RKIP-mediated
suppression of metastasis involves a MAPK/Myc/Lin28/Let-
7/HMGA2 signaling pathway. RKIP was found to repress MAPK
expression leading to attenuated transcription of Lin28 by
Myc. Inhibition of Lin28 promotes Let-7 expression leading to
inhibition of HMGA2 which is a driver of tumor metastasis.
For breast cancer, first-line chemotherapy including treatment
with taxanes such as paclitaxel typically induces 30–70%
therapeutic response rates. However, many patients develop
metastasis and/or tumor relapse after 6–10 months (Seo et al.,
2007). Lin28 was found to mediate resistance of breast cancer
cells to paclitaxel by modulating p21, Rb, and Let-7a miRNAs
(Lv et al., 2012). As compared to cells expressing a low level of
LIN28A, T47D cancer cells with high expression of Lin28 was
shown to be more resistant to paclitaxel. While stable expression
of Lin28 in cancer cells with low Lin 28 levels significantly
reduced their sensitivity to paclitaxel, LIN28A knockdown in
T47D cells effectively sensitized them to the drug. In another
study, LIN28A was reported to be responsible for breast cancer
cell resistance to radiation (Wang et al., 2013). Highest expression
level of LIN28A was found in T47D cancer cells which were most
resistant to radiation treatment. Stable expression of LIN28A
not only rendered cancer cells more resistant to radiation, but
dramatically inhibited radiation-induced apoptosis. On the other
hand, down-regulation of LIN28A expression or overexpression
of let-7a miRNA effectively augmented cancer cell sensitivity
to radiation. It was proposed by the authors that Lin28 might
regulate radioresistance of breast cancer cells through H2A.X
and caspase-dependent signaling pathways. In another study,
LIN28A/let-7 axis was found to be involved in the resistance of
human lung and pancreatic cancer cells with a K-RAS mutation
(Oh et al., 2010). Overexpressing let-7a or decreasing LIN28A
expression, cancer cells became more sensitive to radiation.
Taken together, novel therapies designed to target LIN28AB
might help achieve better therapeutic outcomes for the treatment
of drug and radiation-resistant tumors and attenuate metastatic
lesions.
LIN28AB AND METABOLOMICS
Several recent reports have discovered roles for the LIN28AB/let-
7 pathway in metabolism. From 2010, the Lin28AB/let-7 axis
was directly implicated in regulation of glucose metabolism
in mammals using transgenic overexpression and conditional
knockout mice. A mouse strain with doxycycline-inducible
Lin28A is characterized by low level, leaky expression in muscle,
skin, and connective tissues in the absence of the inducer
(Zhu et al., 2010). These mice have increased body size,
delayed onset of puberty, insulin insensitivity, and increased
glucose metabolism that results from a shift toward glycolysis
and elevated lactate production. Increased glucose uptake
is attributed to Lin28ab-mediated repression of let-7 and
consequent suppression of the Insulin-PI3K-mTOR pathway. In
mice with inducible let-7 overexpression, similar effects were
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found as those observed in Lin28a conditional knockout (Zhu
et al., 2011). Increased let-7 expression reduced body size and
led to hyperglycemia and glucose intolerance. Whole body
overexpression of both Lin28a and let-7 resulted in no overt
metabolic defects due to the antagonistic actions of these factors.
Changes in cellular bioenergetics play a central function
in tissue repair where Lin28a expression promotes recovery
preferentially in young mice (Shyh-Chang et al., 2013b).
Specifically, mice ectopically expressing Lin28a in several models
of tissue injury such as shaved hair, distal digit amputation,
and ear clipping showed the induction of the anagen of the
hair, the repair of the digits, and the healing of the ear
wounds, respectively. For tissue repair, both let-7 dependent
and independent activities of Lin28a are required. The role
of Lin28a in tissue regeneration is attributed to elevated
glycolysis as well as mitochondrial OxPhos activity resulting
from the translational enhancement of metabolic enzymes such
as phosphofructokinase, pyruvate dehydrogenase, and isocitrate
dehydrogenase.
In cancer cells, the embryonic function of LIN28A/LIN28B
is subverted to induce a metabolic shift from oxidative
phosphorylation to glycolysis. For example, overexpression of
either LIN28A or LIN28B in liver cancer cells promotes the
Warburg effect as manifested by elevated glucose uptake,
lactate production and oxygen consumption rate, which
were reversed upon exposure to let-7 mimetics (Ma et al.,
2014). LIN28 meditated post-transcriptional regulation of the
metabolic enzyme PDH kinase 1 (PDK1) is thought to
contribute to these effects. In mouse ESCs, the Lin28a/let-7 axis
regulates the Thr-Gly-SAM pathway (Shyh-Chang et al., 2013a).
Overexpression of Lin28a resulted in an increase in Thr-Gly-
SAM metabolites while overexpression of let-7 resulted in a
concomitant decrease of these metabolites. LIN28A in concert
with NANOG, OCT4, and SOX2 can reprogram differentiated
cells back into an induced pluripotent state (Yu J. et al.,
2007). However, under pathological circumstances, aberrantly
expressed LIN28A/LIN28B can stimulate the development of
highly aggressive, poorly differentiated tumors. Notably, all
reprogramming factors used to transform adult fibroblasts back
to IPS cells, have been linked to oncogenesis and many poorly
differentiated aggressive human tumors had an embryonic stem-
cell like gene expression signature (Ben-Porath et al., 2008;
Viswanathan and Daley, 2010). The phenomenon suggests
that inducing pluripotency shares commonalities with the
aberrant epigenetic reprogramming and alterations in cellular
bioenergetics that happens during tumorigenesis (Figures 4, 5).
GENETICALLY ENGINEERED MOUSE
MODELS OF LIN28A/LIN28B-EXPRESSING
CANCERS
Clinical data and cell culture studies implicate LIN28AB in
poor prognosis human cancer. A direct role for LIN28AB in
mammalian cancer has been independently confirmed in several
studies using genetically engineered mouse (GEM) models. To
date, several reported studies have shown that enforced Lin28AB
expression is sufficient on its own in select cases to cause cancer
and more broadly promotes tumor growth and/or metastasis
in existing GEM cancer models. Many of the GEM cancer
studies have used mice with inducible Lin28 that were generated
by the Daley lab. Specifically, flp-mediated recombination was
perfomed in KH2 ES cells, resulting in a single-copy integration
downstream of the Col1a1 gene that has a TetO minimal
CMV promoter—ORF (either mouse Lin28a or human LIN28B)-
pA signal. Therefore, Lin28 transgene expression occurs in
the presence of the reverse Tet-transcriptional activator in
combination with doxycycline induction. These inducible strains
have been used in four cancer studies to date with a focus
on colon cancer, liver cancer, Wilms tumor, or mast cell
malignancies.
For colon cancer, we performed immunohistochemistry on 45
human tumor samples where 19 were LIN28A-positive while 14
expressed LIN28B (Piskounova et al., 2011). Three independent
groups have each analyzed more than 200 colon cancer samples
where LIN28AB expression has been shown to be associated with
poor prognosis (see Table 1). To investigate a direct role for
Lin28ab in mammalian intestinal and colon cancer, the Daley lab
usedmice with doxycycline inducible Lin28A/LIN28B expression
that was limited to cells where Villin-Cre had acted (Tu et al.,
2015). They showed that induced Lin28A/LIN28B expression
was sufficient to cause tumors restricted to the small intestine.
No colon tumors were observed. Induced Lin28ab expression in
the context of ApcMin/+ mice accelerated tumor development
and increased tumor incidence. Strikingly, induced Lin28AB
expression led to a substantial increase in colon tumors and
the resulting tumors became metastatic relative to ApcMin/+
mice that lack Lin28ab. These results clearly show that Lin28AB
expression in mouse cancer models can significantly improve
their overall quality to mimic human disease.
Many human liver cancers are characterized by LIN28B
overexpression. Nguyen and colleagues demonstrated that
induced, liver-specific expression of LIN28B was sufficient to
cause hepatocellular carcinomoma (Nguyen et al., 2014). In
addition, they showed that an inducible Albumin-MYC mouse
model for liver cancer has 50% mortality by ∼40 days post-
induction; however, genetic ablations of both Lin28a and Lin28b
in the liver resulted in∼70% of Albumin-MYCmice surviving to
150 days post-induction, the time at which the study terminated.
Similarly, Lin28b deletion extended survival in another liver
cancer mouse model, LAP-MYC. As another example, a
significant proportion (∼15%) of Wilms tumor, the most
common pediatric kidney cancer, is characterized by LIN28B
expression (Urbach et al., 2014). These authors further showed
that LIN28B expression in human Wilms tumor correlates with
higher relapse risk and poor prognosis and that induced LIN28B
expression in the embryonic mouse kidney caused this disease.
In addition to the described research that was performed by
or in collaboration with the Daley lab, other research teams
have investigated Lin28b in cancer using transgenic mice. For
example, transgenic mice with targeted LIN28B overexpression
in the sympathetic adrenergic lineage, hematopoietic tissues,
and intestinal epithelium caused neuroblastoma, peripheral T-
cell lymphoma (PTCL), and intestinal/colon adenocarcinoma,
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respectively (Beachy et al., 2012; Molenaar et al., 2012; Madison
et al., 2013). In neuroblastoma cells, LIN28B blocks neuronal
differentiation and upregulates MYCN post-transcriptionally by
blocking the let-7 microRNAs. In the PTCL model, LIN28B
led to upregulation of IL-6, a let-7 microRNA target (Beachy
et al., 2012), and is consistent with earlier work from the Struhl
lab that linked molecular inflammation and cancer through a
positive feedback loop involving NF-κB, LIN28B, let-7, and IL-6
(Iliopoulos et al., 2009).
A major deficiency in the current GEM models is that
there is none for LIN28AB-positive cancers that primarily affect
women. As Tables 1, 3 illustrate, LIN28AB expression occurs
frequently in ovarian cancer and seems responsible in part for
the development of drug resistant tumors. In addition, LIN28AB
is also significant in breast cancer. Specifically in 33 breast
cancer tumors that we interrogated by immunohistochemistry,
9 were LIN28A+, 10 were LIN28B+, and none were positive
for expression of both genes (Piskounova et al., 2011). Let-7
levels were negatively correlated with LIN28AB expression as
expected in these samples. Furthermore, LIN28A and LIN28B
expression is correlated with HER2-positive and triple negative
breast cancer, respectively. Multiple research groups have
independently validated this result using immunohistochemical
methods and analysis of TCGA breast cancer samples (Feng
et al., 2012; Xie et al., 2014; Shen et al., 2016). To date, no GEM
models have been reported to date that faithfully recapitulate
LIN28A expression in HER2+ or LIN28B in triple negative
breast cancer. These preclinical mouse models are essential to
understand how LIN28AB contributes to disease in vivo and to
test novel, molecularly targeted drugs.
BIOCHEMICAL SCREENS FOR
INHIBITORS OF LIN28AB OR THE
LIN28A-INTERACTING TUTase ZCCHC11
Considering the oncogenic role of LIN28AB, it is evident
that inhibition of the LIN28AB/let-7 pathway is an attractive
molecular target for cancer chemotherapy. Four high throughput
screens have been reported whose objective is the identification
of pharmacologically active small molecules that disrupt
LIN28AB-mediated let-7 repression. Lin and Gregory used a
biochemical assay to find small molecule inhibitors of the mouse
TUTase Zcchc11 (Lin and Gregory, 2015a). They screened
14,822 compounds and identified 91 hits in the primary screen.
Many of the identified compounds were non-specific, thiol-
containing inhibitors as their screen was done in the absence
of reducing agents such as dithiothreitol or β-mercaptoethanol.
Of the candidate inhibitors that survived biochemical scrutiny
under reducing conditions, aurothioglucose hydrate was further
validated to block pre-let-7 uridylation in vivo. In contrast to
this screen that looked for a TUTase inhibitor, the other reported
screens sought to identify compounds that block the ability of
LIN28AB to bind RNA. Roos et al. used a protein/RNA FRET
assay to test ∼16,000 compounds for molecules that blocked
the LIN28B/let-7 interaction (Roos et al., 2016). They identified
a compound N-methyl-N[3-(3-methyl[1,2,4]triazolo[4,3-
b]pyridazin-6-yl)phenyl]acetamide that phenocopied LIN28B
siRNA in the restoration of let-7 levels in the Huh7 liver
cancer cell line. Lightfoot et al. developed a biophysical high
throughput screening assay to detect small molecule inhibitors
of the LIN28A-pre-let-7 interaction (Lightfoot et al., 2016). They
screened a library of 2,768 pharmacologically active compounds
and found two compounds 6-hydroxy-DL-DOPA, a dopamine
precursor, and SB/ZW/0065, a benzo[a]phenoxazine derivative
validated in vitro. Lim et al. also used a FRET-based high-
throughput screen to find molecules that disrupt the interaction
between LIN28A and pre-let-7a (Lim et al., 2016). They screened
an in-house library of 4,500 drug-like compounds and identified
a benzopyaranylpyrazole-based compound (Compound 1) as a
lead hit. This compound upregulated the levels of the let-7 family
members in the human choriocarcinoma cell line, JAR as well
as PA-1 cells. Furthermore, in JAR cells, exposure to Compound
1 resulted in a reduction of the let-7 targets c-Myc, HMGA2
and Ras. Overall, these screens have successfully identified small
molecules that upon further optimization and refinement may
provide therapeutic benefit to patients bearing LIN28A/B tumors
and improve prognosis. Since this research is in its infancy,
no clinical trials are underway interrogating LIN28AB and/or
TUTase inhibitors.
THE LIN28AB/LET-7 PATHWAY AS A
MOLECULAR TARGET FOR NOVEL
ANTICANCER THERAPEUTICS
Conventional cancer treatments including surgery,
chemotherapy, and radiation therapy have limited effect
against metastatic tumors, drug-resistant recurrent tumors, and
CSCs. Novel strategies that can better address these problems
are urgently required. Overexpression of LIN28A/LIN28B
that results in dysregulation of let-7 microRNAs are essential
pathological events in tumorigenesis and progression of many
human cancers. The fundamental roles of LIN28A/LIN28B in
CSCs, metastasis, resistance to chemotherapy and radiation
therapy make them emerging molecular targets for novel
anticancer treatments. It is conceivable that correcting
aberrant LIN28AB/let-7 signaling pathway will help overcome
shortcomings of current anticancer treatments. In mammals,
LIN28A and LIN28B are not expressed in adult somatic tissues
with few exceptions such as expression in some cardiac and
skeletal muscle cells (Yang and Moss, 2003). Evidence from
Lin28a and Lin28b knockout mice showed that ablation of
either gene in 6-week old mice does not cause overt phenotypes
such as differential growth (Shinoda et al., 2013). Accordingly,
therapeutics such as shRNAs, siRNAs, and chemical compounds
that downregulate LIN28A or LIN28B expression or functional
activity are unlikely to have harmful side effects in patients. As
mentioned earlier, there is already evidence that downregulation
of LIN28A in chemotherapy and radiation-resistant breast
cancer cells enhanced their sensitivity to the treatments (Lv et al.,
2012; Wang et al., 2013). Suppression of LIN28A by shRNA in
human glioblastoma cells caused cell cycle arrest in the G1 phase,
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enhanced apoptosis, and delayed cell proliferation (Qin et al.,
2014). Tristetraprolin (TTP) is an AU-rich element binding
protein that functions to regulate gene expression by binding
to AU-rich elements in the 3′-UTR of mRNA transcripts and
promoting degradation (Blackshear, 2002). Dysregulation of
TTP expression and activation of proto-oncogenes coexist in
various cancers (Brennan et al., 2009). Intriguingly, TTP was
shown to increase levels of mature let-7a, let-7b, let-7f, and
let-7g miRNA by post-transcriptionally inhibiting LIN28A
expression in ovarian cancer cells. Overexpression of TTP in
PA1 ovarian cancer cells successfully suppressed cell growth via
let-7b-meidated inhibition of CDC34, which is a downstream
target gene of the let-7 family (Kim et al., 2012). In another
study, depletion of LIN28A by shRNA reduced in vitro invasion
ability of bone metastatic breast cancer cells (Dangi-Garimella
et al., 2009). Furthermore, their in vivo study showed that the
metastatic ability of LIN28A-depleted breast cancer cells was
significantly impaired.
It is also a feasible to increase let-7 level by interfering with
binding of LIN28A/LIN28B to pre-let-7. LIN28AB inhibits let-
7 maturation by first interacting with the terminal loop of let-7
precursors. Thus, any small molecules such as aptamers which
can effectively block the binding of LIN28AB to immature let-
7 will increase let-7 levels. Both in vitro and in vivo studies
have shown that maturation of 7S21L, a chimeric pri-let-7g
stem and with the miR-21 terminal loop, is not regulated by
LIN28AB, highlighting the fact that the loop is the primary
RNA determinant for the LIN28AB interaction (Piskounova
et al., 2008; Zhu et al., 2011). Coexpression of 7S21L with
LIN28AB in NIH/3T3 cells successfully nullified the ability of
LIN28AB to transform cells suggesting let-7 loop mutants might
be effective in treating cancers caused by increased level of
LIN28AB (Viswanathan et al., 2009). In addition, a truncated
stem loop short RNA duplex which has a similar structure to
let-7 miRNAs might also help increase let-7 level by acting as a
competitive binding inhibitor for LIN28AB. Moreover, synthetic
let-7 mimic elicited remarkable anticancer effects onmice human
lung cancer xenografts. Treatment with a single dose of let-
7b mimic immediately before tumor implantation successfully
delayed tumor formation. In addition, intratumoral injections of
the synthetic miRNA on established mice tumors also blocked
tumor growth (Esquela-Kerscher et al., 2008). In another study,
i.v. injection of synthetic let-7b conjugated with a neutral lipid
emulsion successfully reduced lung tumor burden in the K-
RAS orthotopic non-small cell lung cancer mouse model (Trang
et al., 2011). Since LIN28A-mediated inhibition of let-7 requires
ZCCHC11 (Hagan et al., 2009; Heo et al., 2009; Piskounova et al.,
2011), small molecules that inhibit functions of this TUTase may
also produce therapeutic benefits in cancer patients. For example,
knockdown of ZCCHC11 by siRNA or shRNA increased the level
of mature let-7 microRNAs in both mouse embryonic stem cells
and human LIN28A-positive cancer cells. Of note, loss of either
LIN28A or ZCCHC11 led to regression of established human
xenograft tumors.
LIN28A/LIN28B plays an important role in the formation of
CSCs. Thus, chemical or small molecular compounds specifically
targeting LIN28/let-7 axis might be more potent in eradicating
CSCs than conventional chemotherapeutics. Metformin, a
diabetes drug, was found to significantly increase let-7a level
in CSCs, reverse cancer cell stemness, and markedly improve
in vivo therapeutic effect of chemotherapeutic (McCarty, 2012).
It was hypothesized that the drug might induce these anti-
CSCs functions through AMP-activated protein kinase (AMPK)-
mediated up-regulation of let-7 miRNAs leading to suppression
of LIN28A/LIN28B expression. However, more studies are
required to investigate the accuracy of the theory.
In fact, some chemotherapeutics, instead of killing CSCs,
can actually enrich CSC populations in tumors. For example,
treatment with 5-fluorouracil or oxaliplatin at clinically relevant
doses on human metastatic colon cancer cells led to 16- to
30-fold enrichment of CD133+ cell population and 2-fold
enrichment of CD44+ cell population. In terms of double-
positive (CD133+/CD44+) CSCs, 5- to 22-fold population
enrichment was observed (Dallas et al., 2009). In a separate study,
treatment with doxorubicin on CD44, CD24, Epcam positive,
and E-cadherin negative ovarian CSCs enhanced their ability to
form colonies and proliferate (Meirelles et al., 2012). Whereas
chemotherapy selectively promotes survival of breast tumor-
initiating cells (BT-ICs), enforced expression of let-7 in drug-
resistant BT-ICs markedly impaired self-renewal ability of the
cells. More importantly, treatment with let-7 not only inhibited
tumor growth, but markedly reduced metastasis to the lung
and liver of tumor-bearing mice (Yu F. et al., 2007). Consistent
with this idea, Mirna Therapeutics, Inc. has a method for let-7
restoration using a chemically modified let-7 microRNA duplex
in preclinical development. Since let-7 is widely and abundantly
expressed in most cells, it would seem less likely to have off-
target effects in comparison to miR-34 replacement therapy.
Ultimately, specific targeting of microRNA replacement therapy
directly to cancer cells would provide the highest chance for
success. To conclude, novel therapeutics which can effectively
reduce LIN28AB expression/activity or increase mature let-7
levels have significant potential to improve therapeutic outcomes
in LIN28AB-expressing cancer in general and specifically, in
metastatic and drug-resistant disease.
CONCLUDING REMARKS
Lin-28 and the microRNA let-7 were initially discovered in
C. elegans as heterochronic genes that regulate developmental
timing. In mammals, LIN28A rose to prominence as one of
four Thomson reprogramming factors used to generate human
induced pluripotent stem cells. LIN28A and its paralog LIN28B
are highly related RBPs and proto-oncogenes whose expression
is largely restricted to development with particularly high levels
in embryonic stem cells. LIN28A and LIN28B exert their
biological functions through repressing the biogenesis of the
tumor suppressor let-7microRNA family as well as modifying the
translation efficiency of mRNAs that it binds. In >15% cancers,
either LIN28A or LIN28B is reactivated. As a result, let-7 is
downregulated, leading to enhanced expression of notable let-
7 targets such as RAS, MYC, and HMGA2 as well as changes
in cellular metabolism. For many cancers that appear not to
express LIN28AB in the tumor, the CSC population is LIN28A
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or LIN28B positive. This population is refractory to many
therapies and is thought to give rise to recurrent and more
deadly disease. In support of this assertion, LIN28AB via a let-
7 dependent mechanism promotes metastasis and resistance to
several frontline cancer treatments including ionizing radiation
and multiple chemotherapies such as taxanes and platinum-
based drugs. It is therefore not surprising that LIN28 expression
correlates with poor prognosis.
We and others have provided proof-of-principle experiments
that LIN28AB are bona fide candidates for cancer intervention.
As LIN28AB expression is limited predominantly to tumor cells
and conditional mouse knockout of either Lin28a or Lin28b
at 6 weeks of age yields no overt phenotypes, it is anticipated
that therapeutics targeting the LIN28/let-7 pathway will have
minimal side effects in patients. We showed that inhibition
of LIN28A or its interacting TUTase ZCCHC11 via siRNA
treatment caused regression of established xenograft human
tumors in mice. This result was phenocopied by application of
a let-7 mimic. Further work revealed that LIN28B represses let-
7 by a distinct mechanism that does not rely on ZCCHC11.
Inhibition of LIN28B also caused the regression of established
xenograft human tumors in mice. Future studies are still needed
to define the precise mechanism(s) that are responsible for
LIN28B-mediated let-7 repression.
Thus, LIN28 is an attractive molecular target for
chemotherapy with the potential to provide benefit to
patients aﬄicted with a subset of poor prognosis cancers.
High throughput biochemical screens recently demonstrated
that small molecules exist that can modulate the LIN28/let-7
pathway. In the future, larger screens with subsequent chemical
optimization of hits hold promise for further pre-clinical
drug development. Future research endeavors will reveal
not only a more precise role of LIN28 in human disease
but also bring to the forefront an exciting frontier in cancer
therapeutics as the LIN28/let-7 pathway is exploited for
the development of a novel class of LIN28 and/or TUTase
inhibitors.
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